JNBA Financial Advisors grew its position in shares of Sanofi SA (NYSE:SNY) by 64.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,160 shares of the company’s stock after purchasing an additional 2,015 shares during the quarter. JNBA Financial Advisors’ holdings in Sanofi were worth $228,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Essex Savings Bank bought a new position in Sanofi during the 4th quarter worth approximately $30,000. Claybrook Capital LLC acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $31,000. Executive Wealth Management LLC acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $34,000. Nkcfo LLC acquired a new stake in shares of Sanofi during the 1st quarter worth approximately $35,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Sanofi during the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.
NYSE SNY traded up $0.02 during mid-day trading on Friday, hitting $43.38. The company’s stock had a trading volume of 2,650 shares, compared to its average volume of 1,049,676. Sanofi SA has a twelve month low of $37.43 and a twelve month high of $45.62. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The company has a market cap of $108.88 billion, a P/E ratio of 13.88, a PEG ratio of 2.41 and a beta of 0.67.
The firm also recently declared an annual dividend, which will be paid on Friday, May 31st. Investors of record on Wednesday, May 8th will be given a $1.7395 dividend. This represents a yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s payout ratio is currently 38.34%.
SNY has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research report on Monday, February 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, January 14th. TheStreet downgraded shares of Sanofi from a “b” rating to a “c+” rating in a research report on Thursday, February 7th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, February 28th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $51.00.
In related news, major shareholder Sanofi sold 131,115 shares of Sanofi stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.00% of the company’s stock.
WARNING: This piece was posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://weekherald.com/2019/05/03/jnba-financial-advisors-has-228000-holdings-in-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: What is a short straddle?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.